Lonquex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing use of chemotherapy treatments, advancements in hematology supportive care, early adoption of pegylated growth factors, improved cancer survival rates, expansion of oncology treatment centers.

The growth in the forecast period can be attributed to growing demand for long-acting supportive care drugs, rising biosimilar competition, increasing cancer patient populations, expansion of outpatient oncology services, continued innovation in hematopoietic growth factors. Major trends in the forecast period include increasing adoption of long-acting g-csf therapies, rising focus on chemotherapy supportive care, growing preference for single-dose treatment regimens, expansion of biosimilar development programs, enhanced emphasis on infection risk reduction.

The rising cancer incidence is expected to drive the growth of the Lonquex market moving forward. Cancer incidence refers to the number of new cancer cases diagnosed in a population during a specific time frame, usually expressed per 100,000 individuals annually. The increase in cancer cases is attributed to factors such as an aging population, lifestyle changes like increased tobacco and alcohol consumption, environmental exposure to carcinogens, genetic predispositions, and advancements in diagnostic capabilities. Lonquex (lipegfilgrastim) helps reduce the risk of infection in cancer patients by boosting the production of white blood cells, which helps mitigate the effects of chemotherapy-induced neutropenia. For example, in February 2024, the World Health Organization (WHO) projected that by 2050, more than 35 million new cancer cases would be diagnosed globally, marking a 77% increase compared to the estimated 20 million cases in 2022. As such, the rising cancer incidence is driving the growth of the Lonquex market.

The expansion of biosimilars is expected to propel the growth of the Lonquex market in the future. Biosimilars are biologic medical products that are highly similar to already approved reference biologic products, with no clinically significant differences in terms of safety, efficacy, or potency. The growth of biosimilars is driven by efforts to contain healthcare costs, patent expirations of biologic drugs, the rising prevalence of chronic diseases, and the increasing acceptance of biosimilars among healthcare providers and patients. Lonquex (lipegfilgrastim) functions as a biosimilar by replicating the natural activity of granulocyte colony-stimulating factor (G-CSF), stimulating neutrophil production and release from the bone marrow, thus lowering the infection risk in chemotherapy patients. For instance, in July 2025, Abbott Laboratories reported that biosimilars had helped European healthcare systems save over $64 billion to date. As such, the expansion of biosimilars is driving the growth of the Lonquex market.

In August 2024, Lotus Pharmaceutical Co. Ltd., a Taiwan-based pharmaceutical company, acquired Teva Pharma (Thailand) Co. Ltd. for an undisclosed amount. This acquisition is part of Lotus Pharmaceuticals' strategy to expand its footprint in Southeast Asia, strengthen its oncology and women's health product offerings, and gain access to Teva's ophthalmic and respiratory portfolio. The move will also enhance Lotus' presence in both hospital and pharmacy channels in Thailand. Teva Pharma (Thailand) Co. Ltd. is known for providing Lonquex in the region.

Major companies operating in the lonquex market are Teva Pharmaceutical Industries Ltd.

North America was the largest region in the lonquex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lonquex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lonquex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the lonquex market by increasing costs of imported active pharmaceutical ingredients, syringe components, auto-injector devices, and biologics manufacturing equipment. Europe and North America are most affected due to reliance on international biologics supply chains, while Asia-Pacific faces cost pressure on biosimilar production inputs. These tariffs are contributing to higher manufacturing expenses and pricing pressure. However, they are also encouraging localized biologics production, domestic fill-finish capabilities, and regional sourcing of injectable drug components.

The lonquex market research report is one of a series of new reports that provides lonquex market statistics, including lonquex industry global market size, regional shares, competitors with a lonquex market share, detailed lonquex market segments, market trends and opportunities, and any further data you may need to thrive in the lonquex industry. This lonquex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lonquex, also known as lipegfilgrastim, is a long-acting granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of white blood cells. It is primarily prescribed for treating severe neutropenia, a condition where neutrophil levels are abnormally low, compromising the body’s ability to fight infections. Neutropenia often arises in patients undergoing chemotherapy for cancer, as chemotherapy can suppress the bone marrow’s ability to produce white blood cells.

The main formulation of Lonquex is the injectable solution for injection, which is available in pre-filled syringes or auto-injectors. This formulation is administered via injection, ensuring rapid delivery and effective therapeutic results, particularly in hospital settings for conditions like neutropenia. Lonquex is used for the prevention of chemotherapy-induced neutropenia, treatment of neutropenia in hematological malignancies, and supportive care during chemotherapy. The patient demographics for Lonquex include adult, geriatric, and pediatric patients. The distribution channels for the drug include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. Key end users include hospitals, oncology clinics, dermatology clinics, and research institutions.

The lonquex market consists of sales of CAR T-cell therapy kits, granulocyte colony-stimulating factor (G-CSF) drugs, and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.